Advertisement

Topics

Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)

19:00 EDT 17 Aug 2017 | Net Resources International

Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML).

Original Article: Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)

NEXT ARTICLE

More From BioPortfolio on "Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...